Please login to the form below

Not currently logged in
Email:
Password:

Zelboraf

This page shows the latest Zelboraf news and features for those working in and with pharma, biotech and healthcare.

Second chance for AstraZeneca’s selumetinib with breakthrough designation

Second chance for AstraZeneca’s selumetinib with breakthrough designation

There are several other MEK inhibitor drugs already on the market, including Novartis’ Mekinst and Roche’s Zelboraf, both licensed for use in melanoma, but none in this indication.

Latest news

More from news
Approximately 10 fully matching, plus 40 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    But there are downsides too. It’s worth noting that Roche’s BRAF-targeting drug Zelboraf (vemurafenib) for melanoma has seen mixed results in other tumours, suggesting that ‘histologic context’ – ie

  • Pharma deals during April 2014 Pharma deals during April 2014

    Indeed a whopping $1.5bn payment depends on the results of the on-going combination trial against Roche's Zelboraf.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Chris Bowden joins Agios Chris Bowden joins Agios

    During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

  • Kite Pharma appoints Zelboraf scientist as CMO Kite Pharma appoints Zelboraf scientist as CMO

    Keith Nolop joins US cancer biotech from Plexxikon. Dr Keith Nolop, one of the chief scientists behind the development of Roche's personalised skin cancer drug Zelboraf, has been appointed chief ... During this time, he was clinical lead for the

  • AstraZeneca hires Roche’s Pascal Soriot as CEO

    This merger has spawned such drugs as cancer treatments Avastin, Herceptin and Zelboraf, and is deemed to be one of the more successful pharma deals of recent years, while during that

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics